The Efficacy of Metacognitive Therapy for Obsessive-compulsive Disorder

Status: Recruiting
Location: See location...
Intervention Type: Behavioral, Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The goal of this clinical trial is to learn if metacognitive therapy can be effective in a Chinese sample of obsessive compulsive disorder (OCD) . The main questions it aims to answer are: Can metacognitive therapy significantly reduce participants' levels of obsessive-compulsive symptoms? Can metacognitive therapy significantly improve participants' metacognitive adaptations? The researchers will compare metacognitive therapy to a control condition without psychotherapy to see if metacognitive therapy is effective in treating OCD. Participants will: Receive the metacognitive therapy intervention or under control conditions for 8 to 15 weeks. Be assessed for symptoms and metacognitive beliefs at pre-intervention, post-intervention and 12 weeks post-intervention

Eligibility
Participation Requirements
Sex: All
Minimum Age: 12
Maximum Age: 60
Healthy Volunteers: f
View:

• two psychiatrists with the title of Deputy Chief Physician or above jointly determine that the above diagnostic criteria were met

• education level of junior high school or above, without mental retardation or audio-visual disorders

• participation in the study is voluntary, and the informed consent is signed by the patient or his/her guardian

Locations
Other Locations
China
Northeast Normal University
RECRUITING
Changchun
Contact Information
Primary
Fan Jiang, Ph.D
Jiangf581@nenu.edu.cn
13943004788
Time Frame
Start Date: 2024-06-11
Estimated Completion Date: 2024-11-01
Participants
Target number of participants: 80
Treatments
Experimental: Metacognitive Therapy
Intervention using metacognitive therapy, with sessions set for 8-15 weeks of 1-2 weekly psychotherapeutic dialogue.
Placebo_comparator: Control Condition
Do not receive any additional psychotherapy in addition to conventional treatment.
Related Therapeutic Areas
Sponsors
Leads: Northeast Normal University

This content was sourced from clinicaltrials.gov